Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of anti-multiple myeloma small interfering ribonucleic acid and its application

A multiple myeloma, ribonucleic acid technology, used in applications, anti-tumor drugs, fermentation, etc., can solve problems such as lack of effective therapeutic molecular targets

Inactive Publication Date: 2017-12-01
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The technical problem to be solved by the present invention is to provide an effective solution to the current lack of effective therapeutic molecular targets in the treatment of multiple myeloma, that is, an anti-multiple myeloma small interfering ribonucleic acid target Polynucleotide, the application of the target polynucleotide in the preparation or screening of anti-multiple myeloma drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-multiple myeloma small interfering ribonucleic acid and its application
  • A kind of anti-multiple myeloma small interfering ribonucleic acid and its application
  • A kind of anti-multiple myeloma small interfering ribonucleic acid and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Design and synthesis of siRNA against SUMO-1 gene

[0053] Design and synthesize SUMO-1 small interfering RNA (siRNA), wherein the target sequence in the SUMO-1 gene of the siRNA is as shown in Table 1:

[0054]siRNA target sequence (CDNA) of table 1 SUMO-1 gene

[0055] Numbering

serial number

sequence

siRNA-1

SEQ ID NO:1

CTGGGAATGGAGGAAGAAG

siRNA-2

SEQ ID NO:2

CAATGAATTCACTCAGGTT

siRNA-3

SEQ ID NO:3

GGACAGGATAGCAGTGAGA

[0056] According to the sequence in the above table, the siRNA sequence was synthesized by Ribo (Guangzhou) Company, and ddH 2 O dilute the synthesized siRNA nucleotide molecules to a concentration of 100 μM for later use. The sequence information and structural information of the resulting siRNA are as follows:

[0057] Fragment sequence of siRNA-1: sense strand 5'CUGGGAAUGGAGGAAGAAG dTdT 3' (as shown in SEQID NO:4 in the sequence listing);

[0058] Antisense strand 3'd...

Embodiment 2

[0063] Example 2: Using siRNA to transfect myeloma cells

[0064] Myeloma cells NCI-H929 (the cells were purchased from ADCC) and RPMI-8226 (the cells were purchased from ADCC) in the logarithmic growth phase were centrifuged for 5 min, the supernatant was discarded, and the cells were resuspended with PBS, and then Centrifuge for 5min. Use the ELX800 microplate reader to adjust the cell concentration to 30×10 4 cells / L, inoculated into a six-well plate overnight. The cationic liposome was lipo2000, and the siRNA-3 obtained in Example 1 was dissolved in water, and the final concentration of the obtained aqueous solution was adjusted to 100 nM. The cationic liposome and siRNA solutions were diluted with optimum respectively, and left at room temperature for 5 minutes for later use. Mix the cationic liposome solution and the siRNA solution so that the liposome fully encapsulates the siRNA, and let it stand at room temperature for later use. After 20 min, add the mixture to t...

Embodiment 3

[0083] Example 3: Effect of SUMO-1 Gene Expression Inhibition on Apoptotic Rates of Different Multiple Myeloma Cells

[0084] Annexin V-FITC-PI kit (purchased from KGI, Shanghai) and flow cytometry (model BD FACS calibur 4, USA) were used for detection.

[0085] Flow cytometry: Suspended cells were collected by centrifugation (2000rpm for 5min); cells were washed twice with PBS (2000rpm for 5min) to collect 1-5×10 5 Cells; add 500 μL Binding Buffer to suspend cells; add 5 μL Annexin V-FITC and mix well, then add 5 μL Propidium Iodide, mix well; room temperature, dark, react for 5-15 minutes; flow cytometry detection.

[0086] MTS method: divide cells into 10 × 10 3Inoculate each well in a 96-well plate, add 20 μl MTS (purchased from Promega) after 48 hours of treatment, 37 ° C, 5% CO 2 After incubating in the cell culture box for 2 hours, use a Flex Station 3 (purchased from Molecular Devices) microplate reader to detect (490 / 690nm).

[0087] From the target polynucleotide ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the fields of biotechnology and medicine, and discloses a small interference ribonucleic acid against multiple myeloma and its application. Wherein the nucleotide sequence of the target polynucleotide is shown in any one of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 in the sequence listing. Excessive SUMOylation is associated with poor prognosis in multiple myeloma. In-depth research on the effect and molecular mechanism of SUMOylated Wnt / β‑catenin on multiple myeloma cell proliferation and apoptosis will help to find the root cause of myeloma progression and further To clarify the prognosis and regulation mechanism of multiple myeloma; and then to develop new therapeutic targets for the key to the recurrence of multiple myeloma. The target DNA provided by the present invention can achieve safer and more effective anti-myeloma treatment, and finally realize the multiple myeloma The cure has very important practical significance.

Description

technical field [0001] The invention relates to the fields of biotechnology and medicine, in particular to a small interference ribonucleic acid against multiple myeloma and its application. Background technique [0002] Multiple myeloma (Multiple myeloma, MM) is the second highest incidence of malignant tumors in the blood system. It is still incurable and seriously threatens the life and health of the people. Conventional chemotherapy and even new drugs have little effect on maintaining self-renewing myeloma stem cells while reducing tumor burden, which is considered to be the key to the ultimate progression and recurrence of MM. Therefore, further research on the source of MM recurrence is urgently needed to develop new, safer and more effective targeted therapies to truly improve the survival and prognosis of MM patients. [0003] Wnt gene is a proto-oncogene, which is the key to the occurrence of various tumors and an important regulatory signal in the development of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/12C12N15/113A61K31/713A61P35/00
Inventor 周莉莉黄禾菁侯建
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com